Total Payments
$9,228
2024 Payments
$2,571
Companies
35
Transactions
145
Medicare Patients
2,094
Medicare Billing
$268,763
Payment Breakdown by Category
Consulting$6,235 (67.6%)
Food & Beverage$2,399 (26.0%)
Education$594.62 (6.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,235 | 4 | 67.6% |
| Food and Beverage | $2,399 | 132 | 26.0% |
| Education | $594.62 | 9 | 6.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,929 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,133 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,664 | 7 | $0 (2023) |
| Astellas Pharma US Inc | $423.79 | 8 | $0 (2024) |
| Merck Sharp & Dohme LLC | $302.64 | 20 | $0 (2024) |
| Janssen Biotech, Inc. | $218.71 | 9 | $0 (2024) |
| Seagen Inc. | $210.95 | 2 | $0 (2023) |
| PFIZER INC. | $192.26 | 5 | $0 (2024) |
| Amgen Inc. | $184.19 | 7 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $176.99 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,571 | 54 | E.R. Squibb & Sons, L.L.C. ($1,522) |
| 2023 | $3,513 | 22 | AstraZeneca Pharmaceuticals LP ($2,009) |
| 2022 | $1,713 | 5 | Novartis Pharmaceuticals Corporation ($1,597) |
| 2021 | $147.79 | 3 | Seagen Inc. ($125.00) |
| 2020 | $658.53 | 41 | Amgen Inc. ($156.69) |
| 2019 | $625.24 | 20 | Bayer HealthCare Pharmaceuticals Inc. ($143.10) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $5.97 | General |
| Category: Oncology | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $4.56 | General |
| Category: Oncology | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Oncology | ||||||
| 11/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Oncology | ||||||
| 10/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Oncology | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Oncology | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Genentech USA, Inc. | Phesgo (Biological), Polivy, Tecentriq | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: BioOncology | ||||||
| 10/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Oncology | ||||||
| 10/01/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.49 | General |
| 09/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.13 | General |
| Category: Hematology | ||||||
| 09/05/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: HEMATOLOGY | ||||||
| 08/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug), REBLOZYL | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Oncology | ||||||
| 08/08/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 397 | 560 | $138,331 | $56,119 |
| 2022 | 5 | 396 | 608 | $132,045 | $52,209 |
| 2021 | 5 | 454 | 646 | $143,385 | $61,097 |
| 2020 | 8 | 847 | 1,506 | $278,871 | $99,337 |
Total Patients
2,094
Total Services
3,320
Medicare Billing
$268,763
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 153 | 286 | $71,786 | $30,861 | 43.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 88 | 88 | $31,856 | $11,216 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 72 | 90 | $16,740 | $5,381 | 32.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 34 | 36 | $7,380 | $3,590 | 48.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $6,279 | $2,711 | 43.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 39 | $4,290 | $2,361 | 55.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 202 | 383 | $71,238 | $26,427 | 37.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 85 | 85 | $30,770 | $10,876 | 35.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 60 | 67 | $20,033 | $10,206 | 50.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 59 | $6,490 | $3,217 | 49.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 14 | $3,514 | $1,484 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 213 | 376 | $70,314 | $28,119 | 40.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 94 | 94 | $34,028 | $13,432 | 39.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 72 | 76 | $22,724 | $11,963 | 52.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 67 | $7,370 | $3,826 | 51.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 32 | 33 | $8,949 | $3,756 | 42.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 290 | 734 | $136,486 | $42,891 | 31.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 81 | 92 | $27,508 | $14,651 | 53.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 236 | 320 | $40,381 | $12,894 | 31.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 98 | 98 | $35,476 | $12,350 | 34.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 74 | 192 | $21,120 | $10,959 | 51.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 44 | 46 | $12,212 | $3,759 | 30.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $3,444 | $1,166 | 33.9% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 12 | 12 | $2,244 | $667.37 | 29.7% |
About Dr. Hafez Halawani, MD
Dr. Hafez Halawani, MD is a Hematology & Oncology healthcare provider based in Alexandria, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1023008372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hafez Halawani, MD has received a total of $9,228 in payments from pharmaceutical and medical device companies, with $2,571 received in 2024. These payments were reported across 145 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($6,235).
As a Medicare-enrolled provider, Halawani has provided services to 2,094 Medicare beneficiaries, totaling 3,320 services with total Medicare billing of $268,763. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Alexandria, LA
- Active Since 10/27/2005
- Last Updated 09/04/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1023008372
Products in Payments
- ENHERTU (Biological) $1,991
- KEYTRUDA (Biological) $236.72
- DARZALEX (Biological) $145.01
- Xofigo (Drug) $143.10
- ELIQUIS (Drug) $125.00
- TUKYSA (Drug) $125.00
- OPDIVO (Biological) $76.50
- REBLOZYL (Biological) $76.37
- Enhertu (Drug) $74.45
- CALQUENCE (Drug) $52.93
- XTANDI (Drug) $52.62
- Orserdu (Drug) $46.79
- XPOVIO (Drug) $43.24
- ERLEADA (Drug) $42.94
- Lenvima (Drug) $38.30
- OPDUALAG (Drug) $38.27
- PIQRAY (Drug) $37.33
- SOMATULINE DEPOT (Drug) $36.66
- Nubeqa (Drug) $33.89
- Tibsovo (Drug) $33.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Alexandria
Vinni Juneja, Md, MD
Hematology & Oncology — Payments: $35,341
Hematology & Oncology $35,341
Dr. Bassam Abi-Rached, M.d, M.D
Hematology & Oncology — Payments: $13,951
Hematology & Oncology $13,951
Dr. Howard Wold, M.d, M.D
Hematology & Oncology — Payments: $9,956
Hematology & Oncology $9,956
Dr. Anastas Provatas, Md, MD
Hematology & Oncology — Payments: $8,801
Hematology & Oncology $8,801
Dr. Christine Ince, M.d, M.D
Hematology & Oncology — Payments: $6,678
Hematology & Oncology $6,678
Dr. Rahul Singh, Md, MD
Hematology & Oncology — Payments: $5,459
Hematology & Oncology $5,459